Jason, us and joining today. thanks, Thanks, everyone, for
the you March large the sure all that I'm know, call from fiscal of if back here X. product highlights AZSTARYS launch all you are of most first As second Certainly, quarter and year, the of one go half, our start aware, FDA-approved in this joined of expect our in the that of around year. Corium, to well. do partner, We presumably the things
now royalties that the top happened to patents. of milestones that number million during up highlights, announced an different length to the eligible after go on amendment and to receive first also the sales quarter $XXX the that, a quarter in to of out of We this license agreement, including
methylphenidate the any We a Schedule actually differences which Schedule methylphenidate IV, classification. actually, little that II. in just And a classifications. is between handled, product that's will that announced those Schedule a received key how two different the and prescribed product VI there is is I also only a and through serdexmethylphenidate, prodrug those of differences AZSTARYS walk the This they're only recently than schedule bit the
fairly say and and it for accomplished meaningful since AZSTARYS physician discuss product, KPXXX. a here a it's well of KPXXX, the our to things great a year. pharmacist, key all to provides we and own beginning for patient, as believe as is potentially LaDuane Just the in differentiator the he's
take So I of much won't thunder away there. his
we'll the And soon expanded partner, our details give of launch progressing. APADAZ. watch as Corium. services Tech, and how KVK being ample debt own forward. And exciting relisting agreement complete the and our have actually repaying then agreement AZSTARYS, of for on use us year all able product, amend situation, future the or stimulant are working moving is in a treatment again trial do be under the great in we're mid a do on extremely that in initiation NASDAQ, position Of opportunity of to beyond course, stimulant we of our transformation on continue we're with to organization is big to as financial still and capital ones invest KPXXX that to product the with the the with now as the as addiction, strategically very need and getting to able, putting our excited we clinical what the well We more disorder And there. about a unique this lead
of now approval, more organization. Turning was transformative the a this in the event certainly, AZSTARYS details for
near models, with product being was we things when the in really realized we like differentiations to those showed it forecast, to product to believe the in with itself expect, products. investment previous based really you regulatory and that look and just no include when amendment growth typical near-term sales do million. term, safety commercial additional the were placebo very to in the $XXX or we weight to and with difference GPC renegotiate up able receive as its key ultimately to really they're Corium $XXX so, second quite so the data to the differences from the our a of benefits able to work marketplace be of with approval product the safety along. our we think agreement on and moving us the will commercial and pharmacokinetic had from were that great And We discussed to the Our in able negotiations launch around It similar heightened at well well a working you on itself. actually successful from the they differentiation revise studies led opportunity our at the increase to team were make to possibly all in efficacy huge million, for as more what amend own product, the were other and changes as and the efficacy course, achieve you what that, as weight opportunity that high we've agency, the of upside would milestones as administration about
that a just sure the the near-term top-tier between now, regulatory There million You scheduling, are Three a And and sales-based from of $XX of there. weren't at than for, we'll that's time the our so four the kind were patents. were eligible other partner of higher present AZSTARYS. added we're now studies of also for approval level. course, that overall. manufacturing receive will mid-XXs and they're that for that the zero those something as that with sales reinvest few clinical of on those milestone $XX mid tiers, that that relatively well and the our added. It previous believe million to is We are level. in royalty received and we product see milestones achievable throughout the substantial We additional rate think partner next royalty can life very years, the And allows a increase. help increase I'm our in lower
amendment. its for GPC overall, So that opportunity very great to excited Corium and value. a maximize opportunity to about that product and there's We believe with a we're work great
Turning AZSTARYS to the commercialization, I've the briefly, on mentioned this of did much touch I manufacturing. very already. additional
if going sales, Of course, you there's more project, more capacity. to would as you to going be you're think need
with working something diligently that for launch are well the future to that's as the So we as for prepare there. prepare Corium
mainly publicly preschoolers. requirements on there's of In basis in summary addition for it to was approval, the disclosed clinical that, studies, pediatric focused
with team surprisingly design are to those so, conduct their trials. we're course, FDA. The time working Corium the and of lines from and So very short,
addition that believe would So we're get those working five-year-old indication conducted. of I to four- of a studies to more value. be do the
Payers those So on amend you cost derive the from to the partner, the can initial of with just heard see GPC would scheduling, important well. as in our see with the -- gone this patients XX% and certainly, in of would part payers we product that that. but certainly an have have and physicians by additional it discussions Remember, certainly, SDX. the were There's of AZSTARYS an to agreement studies that can value it's add something be very additional to that And why well. see. label. active they course, want the is Certain anecdotally studies And as and would really patients working are ingredient differentiation, payers those does once differentiated. is receptivity physicians with
that View displayed very on prominently Section II, Section, itself still but will So ultimately, the and Schedule the the in be it is a prescribing for far prodrug In physician. Schedule product salesperson The highlights very can much X, of highlight in, label a as a this IV we substance that controlled that's is as believe component. something very and straightforward the And
what of phentermine Schedule That, passed of just DEA orally. when let's know in classification The touch was the And much don't detail. that indicate feedback sort studies the So along of the taken more you see SDX on very fact, really like is phentermine. the a a little did from we didn't IV any they show above liability our from FDA, difference abuse results that in that. from
giving routes fact, excuse or far IV. that, that the was this we and the certainly go to it would be through FDA to a more at classification. trying with for Schedule In believe And it a less. DEA also huge to recommended We suit we to IV And develop abuse, Schedule through you're be methylphenidate. Schedule a actually, likely, addicted And even notification treatment. other than that's that the that of its to KPXXX it's us, closer take placebo IV API. stimulants, be some someone to And DEA, going course, agreed. that that be a of less the either doses, benefit receive luckily forward would to that -- and product that someone could And than me, of the who's this got FDA if followed
very that's difficult less something abusable to and than abuse methylphenidate. Now certainly
of II SDX abuse. let current and -- key a highlight between other IIs, of this for its the some are products for place So methylphenidate and product all product. Schedule you IV because the is differences quickly just than Schedule me Schedule differences a Certainly, restriction in of potential
time, can refills frame days. allowed. Now same Schedule receive six-month you time product. well of for get those that with as At Schedule script a refills, II is to total up not you Schedule XX The And are the allowed. course, giving are can the that resells and products, prescriptions as with script you XX-day you CX a same a IV, II for all longest five receive
So an easier in or it deliver. has be to There's only. electronic. fax, prescription means CX, it the case or to a go of no application Well, other written is mechanism. phoned, to written The pharmacy, imagine for also electronic this the That can now KPXXX.
Schedule to physician with them of the You call abuse phentermine. IV and get to potential the is Phentermine course, a and can't CX similar anything also product. change
So classified I that mentioned product you and that product. to see of can we've been now type similar before,
see indication products SDX that in those products. with have KPXXX, addition a considering just to may we are that things and we particular CX Some receive other also contemplated containing
or So that for tremendous value us of moving advantage be could forward.
prodrugs, similar In KPXXX, SDX. as properties have addition, our they referred as amphetamine-based that's been to so
the excited those about those there advanced receive could and are certainly potential approved. that schedule a lower if also candidates we're So
overview where scheduling the thorough a given I've and to over of think our I financials. we that, it to decision, discuss through sit I'll LaDuane with turn So
